Literature DB >> 26104649

The six stages of pre-eclampsia.

Cwg Redman1.   

Abstract

For many years pre eclampsia has been considered to be a two-stage disease. The first stage comprises poor placentation. The second stage is the clinical expression of the disease namely new hypertension and new proteinuria. The first stage is preclinical and symptomless, which evolves between weeks 8 and 18 of pregnancy, when the uteroplacental circulation is established by spiral artery remodelling. Its consequence is dysfunctional perfusion of the intervillous space of the placenta with oxidative and haemodynamic stress. The damaged placenta releases excessive pro-inflammatory and antiangiogenic factors into the maternal circulation. With increasing knowledge, this model has become inadequate. First the antecedents of poor placentation have become clearer and are immunological in origin, reflecting the mother's ability to accommodate to the genetic foreignness of her unborn child. They begin, as discussed already in this meeting, with preconceptual tolerisation of the mother to the semen of the prospective father of her child. A lack of tolerisation, arising from a short interval between first coitus and conception increases the likelihood of poor placentation and pre-eclampsia (Stage 1). This is presumed to affect the health and growth of the embryo immediately after implantation but there is little evidence of this at the moment (Stage 2). Placentation begins after week 8 when the uteroplacental circulation, which previously has been closed by trophoblast plugs in the spiral arteries, begins to open. Defective placentation may arise from premature opening, and perfusion of the intervillous space by oxygenised arterial blood before the placenta is equipped to cope with the stress. Placentation extends over about 10 weeks and, when it is defective, constitutes stage 3 of pre-eclampsia. Stages 4-6 all occur in the second half of pregnancy. Stage 4 is associated with excessive or deficient placental derived factors in the mother's blood, secondary to placental damage, before the appearance of clinical signs. When the diagnosis of pre-eclampsia can be made stage 5 has begun. Stage 6 affects less than half of women with pre-eclampsia. It is the superimposition of a second and later spiral artery lesion called acute atherosis, which has some resemblance to atherosclerosis, which is suffered by middle and old-aged, non-pregnant adults. Its importance is that it further reduces uteroplacental perfusion and predisposes to spiral artery thrombosis, which underlies the occurrence of placental infarcts. The evidence for and the mechanisms of these multiple stages will be briefly presented.
Copyright © 2014.

Entities:  

Year:  2014        PMID: 26104649     DOI: 10.1016/j.preghy.2014.04.020

Source DB:  PubMed          Journal:  Pregnancy Hypertens        ISSN: 2210-7789            Impact factor:   2.899


  17 in total

Review 1.  A best practice position statement on the role of the nephrologist in the prevention and follow-up of preeclampsia: the Italian study group on kidney and pregnancy.

Authors:  Giorgina Barbara Piccoli; Gianfranca Cabiddu; Santina Castellino; Giuseppe Gernone; Domenico Santoro; Gabriella Moroni; Donatella Spotti; Franca Giacchino; Rossella Attini; Monica Limardo; Stefania Maxia; Antioco Fois; Linda Gammaro; Tullia Todros
Journal:  J Nephrol       Date:  2017-04-22       Impact factor: 3.902

Review 2.  Hypertension in Pregnancy: Defining Blood Pressure Goals and the Value of Biomarkers for Preeclampsia.

Authors:  Pitchaphon Nissaisorakarn; Sairah Sharif; Belinda Jim
Journal:  Curr Cardiol Rep       Date:  2016-12       Impact factor: 2.931

3.  Plasma concentrations of soluble endoglin in the maternal circulation are associated with maternal vascular malperfusion lesions in the placenta of women with preeclampsia.

Authors:  Mandy J Schmella; Vanessa Assibey-Mensah; W Tony Parks; James M Roberts; Arun Jeyabalan; Carl A Hubel; Janet M Catov
Journal:  Placenta       Date:  2019-03-01       Impact factor: 3.481

Review 4.  Narrative review of the relationship between the maternal-fetal interface immune tolerance and the onset of preeclampsia.

Authors:  Fangyuan Luo; Jun Yue; Lingling Li; Jie Mei; Xinghui Liu; Yu Huang
Journal:  Ann Transl Med       Date:  2022-06

Review 5.  What a paediatric nephrologist should know about preeclampsia and why it matters.

Authors:  Giorgina Barbara Piccoli; Massimo Torreggiani; Romain Crochette; Gianfranca Cabiddu; Bianca Masturzo; Rossella Attini; Elisabetta Versino
Journal:  Pediatr Nephrol       Date:  2021-11-04       Impact factor: 3.651

Review 6.  Hypertension in CKD Pregnancy: a Question of Cause and Effect (Cause or Effect? This Is the Question).

Authors:  Giorgina Barbara Piccoli; Gianfranca Cabiddu; Rossella Attini; Silvia Parisi; Federica Fassio; Valentina Loi; Martina Gerbino; Marilisa Biolcati; Antonello Pani; Tullia Todros
Journal:  Curr Hypertens Rep       Date:  2016-04       Impact factor: 5.369

Review 7.  A Dormant Microbial Component in the Development of Preeclampsia.

Authors:  Douglas B Kell; Louise C Kenny
Journal:  Front Med (Lausanne)       Date:  2016-11-29

8.  Immunological Tolerance, Pregnancy, and Preeclampsia: The Roles of Semen Microbes and the Father.

Authors:  Louise C Kenny; Douglas B Kell
Journal:  Front Med (Lausanne)       Date:  2018-01-04

9.  Primary prevention of preeclampsia: myth or reality?

Authors:  Julian Alberto Herrera
Journal:  Colomb Med (Cali)       Date:  2015-12-30

10.  Delayed Lactogenesis II and potential utility of antenatal milk expression in women developing late-onset preeclampsia: a case series.

Authors:  Jill Demirci; Mandy Schmella; Melissa Glasser; Lisa Bodnar; Katherine P Himes
Journal:  BMC Pregnancy Childbirth       Date:  2018-03-15       Impact factor: 3.007

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.